U.S. ITC Initiates 337 Investigation on STIIIZY and ALD

Regulations by 2FIRSTS, edited by Sophia
Mar.01.2024
U.S. ITC Initiates 337 Investigation on STIIIZY and ALD
ITC launches investigation into e-cigarette companies STIIIZY and ALD for alleged patent infringement based on complaint by PAX Labs.

On February 29, according to the official website of the United States International Trade Commission (ITC), the ITC has decided to conduct a Section 337 investigation on certain atomization devices, their components, and products containing the same products. This investigation involves companies such as STIIIZY and ALD.

 

This investigation is based on a complaint filed by PAX Labs Inc. on January 30, 2024, and supplemented on February 19, 20, and 21, 2024. The complaint alleges infringement of patents claimed by the complainant, involving the import and sale of certain oil vaporization devices, their components, and products containing the same in the United States. The complainant has requested the ITC to issue a limited exclusion order and a cease and desist order.

 

ITC has identified the following respondents in this investigation:

 

  • STIIIZY IP LLC, formerly known as STIIIZY, LLC, located in Los Angeles, California, USA; 
  • ALD Group Limited, based in Guangdong, China; 
  • ALD (Hong Kong) Holdings Limited, located in Hong Kong, China; 
  • STIIIZY Inc., also known as Shryne Group Inc., situated in Los Angeles, California, USA. 

 

The International Trade Commission (ITC) has not made any decisions yet on the substantive issues of the case initiated through investigation (337-TA-1392). The Chief Administrative Law Judge of the ITC will assign this case to an Administrative Law Judge (ALJ), who will schedule and conduct an evidentiary hearing. The ALJ will make an initial determination on whether there is a violation of Section 337, which can be reviewed by the Commission.

 

Within 45 days of the investigation being initiated, the ITC will determine the target date for completing the investigation. Remedial orders in ITC Section 337 cases take effect upon publication and become final within 60 days of publication, unless vetoed by the United States Trade Representative for policy reasons within that 60-day period.

 

Previously, according to a report by Bloomberg on January 30th, e-cigarette manufacturer Pax Labs Inc. has filed a lawsuit against its competitor Stiiizy Inc. and its manufacturer ALD Group Ltd (ALD) for infringing on four of its patents.

 

Pax Labs alleges that Stiiizy and ALD, headquartered in Hong Kong, China, are manufacturing and selling vaporization devices, including batteries and pods, in a manner similar to Pax Labs' patented technology.

 

Pax Labs has obtained U.S. patents 11,369,756, 11,369,757, 11,766,527, and 11,759,580, which are related to methods for leak-proof pods and related devices. Pax Labs has alleged that these two companies have infringed upon the aforementioned patents.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
China’s tobacco tax debate is moving from whether to raise prices to how the tax system should be designed. At a Beijing forum on World No Tobacco Day, experts discussed higher specific excise taxes, minimum tax burdens and dynamic adjustments linked to income and inflation. The issue also connects to China’s broader consumption tax reform, health financing and chronic disease costs. Public reports did not mention e-cigarettes, heated tobacco, nicotine pouches or other new nicotine products.
Jun.11
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Tobacco Farming in the New Nicotine Era: Why Indian Farmers Struggle to Transition — Contributed by Samrat Chowdhery
Tobacco Farming in the New Nicotine Era: Why Indian Farmers Struggle to Transition — Contributed by Samrat Chowdhery
In this contributed article to 2Firsts, Mumbai-based journalist and harm reduction advocate Samrat Chowdhery examines India’s tobacco transition from the perspective of agriculture, supply chains and regulation. As noted by 2Firsts, India offers a relevant case for understanding how new nicotine technologies may affect not only consumption, trade and policy, but also tobacco farming.
Special Report
May.29
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 has passed final stage in the Dáil and will move to the Seanad, with measures to limit vape flavours to tobacco or unflavoured products and tighten rules on packaging colours, retail advertising, in-store displays and sales of nicotine pouches to minors.
News
Jun.26 by 2Firsts Perspectives
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18